Form 8-K - Current report:
SEC Accession No. 0001558370-25-002174
Filing Date
2025-03-04
Accepted
2025-03-04 16:26:28
Documents
16
Period of Report
2025-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20250304x8k.htm   iXBRL 8-K 42054
2 EX-1.1 ymab-20250304xex1d1.htm EX-1.1 343641
3 EX-5.1 ymab-20250304xex5d1.htm EX-5.1 13655
4 GRAPHIC ymab-20250304xex5d1002.jpg GRAPHIC 4756
  Complete submission text file 0001558370-25-002174.txt   596375

Data Files

Seq Description Document Type Size
5 EX-101.SCH ymab-20250304.xsd EX-101.SCH 3409
6 EX-101.LAB ymab-20250304_lab.xml EX-101.LAB 15924
7 EX-101.PRE ymab-20250304_pre.xml EX-101.PRE 10316
18 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20250304x8k_htm.xml XML 4801
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 25704980
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)